Article Hero

Pfizer/BioNTech COVID-19 vaccine shows a robust immune response in kids

Miguel A. Rodriguez
Miguel A. Rodriguez
20 September 2021
One of the most touted pharmaceutical duos since the pandemic started – Pfizer/BioNTech – released news about the immune response of their COVID-19 vaccine for 5–11-year-old volunteers

The two companies revealed the vaccine generated a robust immune response in their Phase II/III clinical trial. The latest results matched those observed in 16-to-25-year-olds. Albert Bourla, Pfizer Chief Executive, stated: "These trial results provide a strong foundation for seeking authorization of our vaccine for children 5 to 11 years old, and we plan to submit them to the FDA and other regulators with urgency."

Following the promising results, Pfizer/BioNTech are planning to ask for authorization as soon as possible for their vaccine to be administrated to children in that age range in the US, Europe, and elsewhere. A rapid approval could help mitigate a potential increase of cases in the fall, given that schools are starting to reopen nationwide.

The companies are looking forward to data on how the vaccine performs on children 2-to-5 years of age and six months to 2 years old as soon as Q4 2021.







Miguel A. Rodriguez
Miguel A. Rodriguez

Miguel worked for major financial institutions such as Banco Santander, and Banco Central-Hispano. He is a published author of currency trading books.